OUR VISION IS TO REDUCE ILLNESS AND DEATH ASSOCIATED WITH FUNGAL DISEASES WORLDWIDE.

News


David W. Denning FRCP FRCPath FMedSci

Posted .

David Denning is an internationally recognised clinician with expertise in fungal diseases and Professor of Infectious Diseases in Global Health at The University of Manchester. He was the founding Director of the UK’s National Aspergillosis Centre in Manchester (2009-2020), the world’s only such centre. David Denning has published more than 600 papers, books and book chapters and lectures worldwide. His writings have been cited over 75,000 times and he has successfully lead many major international collaborative science, diagnostic and treatment projects and clinical guidelines, with subsequent publication in Nature, the New England Journal of Medicine and the Lancet. He is the Founder of two University spinout biotechnology companies – F2G Ltd (antifungal drug discovery and development) and Myconostica Ltd (molecular diagnostic tests for fungi).

David is Chairman of the Editorial Board of The Aspergillus Website (1998-) accessed by >100,000 computers per month and the educational LIFE website. He has chaired the Scientific Committees of several international fungal infection meetings and co-chairs the alternate year Advances Against Aspergillosis meetings, attracting ~400 delegates from >120 countries. He is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group and the British Society for Medical Mycology Standards of Care committee and a member of the SEARO Task Force on AMR (2019 -).

David and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company. He acts or has recently acted as a consultant to Scynexis, Pulmatrix, Zambon, iCo Therapeutics, Roivant, Biosergen, Bright Angel Theraputics and Fujifilm. In the last 3 years, he has been paid for talks on behalf of Hikma, Gilead, Merck, Mylan and Pfizer.

David is Chief Executive of GAFFI, with responsibility for all functions and advocacy outside of Kenya. He is part time.

Profile of David Denning Khalaj Iran Biomed J 2018

University of Manchester and ORCID Profile